Randomized, Placebo-controlled Study to Evaluate Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab with or without Lenvatinib as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer
Study Type/Phase: Phase III
Status: Not Recruiting
The purpose of this trial is to evaluate the safety and effectiveness of lenvatinib in metastatic non-squamous non-small cell cancer (NSCLC) that has not yet been treated. Lenvatinib is a type of targeted therapy known as a receptor tyrosine kinase inhibitor (RTKI) that may slow the rate at which cancer cells grow and may help cut off the blood supply that feeds the cancer. This trial will see how well lenvatinib works when combined with standard of care chemotherapy and pembrolizumab, compared to these treatments alone, for this type of NSCLC. In this trial, patients will be randomized to receive lenvatinib or a placebo in addition to their regular treatment regimen for lung cancer.
Speak with your doctor to determine whether you meet the criteria for participation in this study, some of the following criteria are included:
|Inclusion Criteria||Exclusion Criteria|
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.